Sugi Predict

Sugi Predict / Compounds / SCHEMBL291949

SCHEMBL291949

SCHEMBL291949

CC(COC(=O)O)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.56
▸ CYP1A2 P05177 3/20 0.51
▸ TSHR P16473 1/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ POLB P06746 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ HTT P42858 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ ABCC4 O15439 1/20 0.40
▸ CACNA1F O60840 1/20 0.40
▸ NR1I2 O75469 1/20 0.40
▸ ABCB11 O95342 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ NR3C1 P04150 1/20 0.40
▸ PGR P06401 1/20 0.40
▸ ABCB1 P08183 1/20 0.40
▸ ADORA3 P0DMS8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL291948 1.00 ALDH1A1 (0.56) ALDH1A1CYP1A2TSHRSMN1; SMN2POLB
SCHEMBL291947 0.90 ALDH1A1 (0.57) ALDH1A1CYP1A2TSHRSMN1; SMN2POLB
SCHEMBL4067427 0.88 ALDH1A1 (0.56) ALDH1A1CYP1A2TSHRSMN1; SMN2POLB
SCHEMBL1970488 0.87 ALDH1A1 (0.55) ALDH1A1CYP1A2TSHRSMN1; SMN2POLB
SCHEMBL4303842 0.87 ALDH1A1 (0.62) ALDH1A1CYP1A2TSHRSMN1; SMN2POLB
SCHEMBL16310441 0.87 ALDH1A1 (0.55) ALDH1A1CYP1A2TSHRSMN1; SMN2POLB
SCHEMBL19899857 0.85 ALDH1A1 (0.50) ALDH1A1CYP1A2TSHRSMN1; SMN2POLB
SCHEMBL3327943 0.83 ALDH1A1 (0.55) ALDH1A1CYP1A2TSHRSMN1; SMN2POLB
SCHEMBL3327050 0.83 ALDH1A1 (0.51) ALDH1A1CYP1A2TSHRSMN1; SMN2POLB
SCHEMBL10527478 0.83 ALDH1A1 (0.51) ALDH1A1CYP1A2TSHRSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4419513-B1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2025-08-27 — — EP disclosed
US-12384800-B2 Antitumoral compounds PHARMA MAR, S.A. (ES) 2025-08-12 — — US disclosed
US-20250243174-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2025-07-31 — — US disclosed
WO-2025077996-A1 SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS PHARMA MAR, S.A. (ES) 2025-04-17 — — WO disclosed
WO-2025050647-A1 IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 晟迪生物医药(苏州)有限公司 2025-03-13 — — WO disclosed
US-12215100-B2 Anticancer compounds PHARMA MAR, S.A. (ES) 2025-02-04 — — US disclosed
EP-4419513-A1 ANTITUMORAL COMPOUNDS Pharma Mar S.A. (ES) 2024-08-28 — — EP disclosed
US-20240166666-A1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2024-05-23 — — US disclosed
US-20240131180-A1 DRUG ANTIBODY CONJUGATES PHARMA MAR, S.A. (ES) 2024-04-25 — — US disclosed
WO-2024074604-A1 COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES INSTITUTO BIOMAR, S.A (ES) 2024-04-11 — — WO disclosed
EP-2231633-A1 ANTITUMORAL COMPOUNDS Pharma Mar S.A. (ES) 2010-09-29 — — EP disclosed
EP-2231590-A1 ANTITUMORAL COMPOUNDS Pharma Mar S.A. (ES) 2010-09-29 — — EP disclosed
EP-2231695-A1 ANTITUMORAL COMPOUNDS Pharma Mar S.A. (ES) 2010-09-29 — — EP disclosed
US-20100048690-A2 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2010-02-25 — — US disclosed
US-20090186938-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2009-07-23 — — US disclosed
WO-2009080761-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2009-07-02 — — WO disclosed
WO-2009080769-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2009-07-02 — — WO disclosed
WO-2009077401-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2009-06-25 — — WO disclosed
EP-2032551-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2009-03-11 — — EP disclosed
WO-2007144423-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2007-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384800-B2 Antitumoral compounds TP53, TOP1, MCL1 ALDH1A1 144/4885CYP1A2 2071/4885TSHR 4670/4885
US-20250243174-A1 ANTITUMORAL COMPOUNDS MCL1, XPOT, GZMB ALDH1A1 318/4885CYP1A2 1153/4885TSHR 3614/4885
US-20100048690-A2 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS RPLP1, PKD1, KRAS ALDH1A1 1692/4885CYP1A2 2929/4885TSHR 4338/4885
US-20240131180-A1 DRUG ANTIBODY CONJUGATES STT3B, STT3A, TTL ALDH1A1 785/4885CYP1A2 1836/4885TSHR 1530/4885
US-20240166666-A1 ANTITUMORAL COMPOUNDS TP53, TOP1, MCL1 ALDH1A1 144/4885CYP1A2 2071/4885TSHR 4670/4885
US-20090186938-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS RPLP1, PKD1, KRAS ALDH1A1 1692/4885CYP1A2 2929/4885TSHR 4338/4885
US-12215100-B2 Anticancer compounds TP53, MCL1, MYC ALDH1A1 795/4885CYP1A2 1940/4885TSHR 4635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.